The 2022 Tandem Meetings | AlloHSCT for R/R LBCL after CAR-T therapy failure
Joanna Zurko
• 14 Apr 2022
Joanna Zurko, MD, Medical College of Wisconsin, Milwaukee, WI, gives an overview of a recent retrospective study analyzing the outcomes of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) receiving allogeneic hematopoietic stem cell transplantation (alloHSCT) after CAR-T therapy failure, mentioning patient characteristics and key data such as one-year progression-free survival (PFS), overall survival (OS), and non-relapse mortality (NRM), as well as neutrophil and platelet recovery. Dr Zurko also gives insight into predictors of inferior outcomes in this patient population. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
